Biblio Discovery — Demo Discovery Service

5 hasil untuk "Baoding Zhang"

Menampilkan 1–5 · 0,54 detik · RSS

  1. Artikel Jurnal

    Inhibiting NEDD4 in triple-negative breast cancer cells reprograms tumor immune microenvironment via the β-TrCP/YAP/ECM axis

    Nan Su; Wenhua Lian; Baoding Zhang dkk.

    Cell Reports Medicine, Vol. 6 No. 10 · 2025 · Inggris · DOAJ Scopus

    Summary: Tumor immune microenvironment greatly influences triple-negative breast cancer (TNBC) progression. Identifying targets to convert “cold” tumors into “hot” tumors holds promise for improving treatment outcomes. Here, we show that high expression of NEDD4, an HECT-type E3 ubiquitin ligase…

  2. Artikel Jurnal

    METTL10‐Mediated PIAS3 Methylation Links Purine Metabolism to Gastric Cancer Progression

    Jinshui Tan; Huiwen Zhou; Jingsong Ma dkk.

    Advanced Science, Vol. 12 No. 48 · 2025 · Inggris · DOAJ Scopus

    Abstract Metabolic dysregulation plays a significant role in the development of gastric cancer (GC). However, the mechanisms that control this change and its impact on GC progression remain poorly understood. In this study, it is demonstrated that methyltransferase‐like 10 (METTL10) is a key…

  3. Artikel Jurnal Teks lengkap

    Low-dose metformin targets the lysosomal AMPK pathway through PEN2

    Teng Ma; Xiao Tian; Baoding Zhang dkk.

    Nature · 2022 · Inggris · OpenAlex Scopus

    Abstract Metformin, the most prescribed antidiabetic medicine, has shown other benefits such as anti-ageing and anticancer effects 1–4 . For clinical doses of metformin, AMP-activated protein kinase (AMPK) has a major role in its mechanism of action 4,5 ; however, the direct molecular target of…

  4. Artikel Jurnal

    A new ALK inhibitor overcomes resistance to first‐ and second‐generation inhibitors in NSCLC

    Yue Lu; Zhenzhen Fan; Su‐Jie Zhu dkk.

    EMBO Molecular Medicine, Vol. 14 No. 1 · 2021 · Inggris · DOAJ Scopus

    Abstract More than 60% of nonsmall cell lung cancer (NSCLC) patients show a positive response to the first ALK inhibitor, crizotinib, which has been used as the standard treatment for newly diagnosed patients with ALK rearrangement. However, most patients inevitably develop crizotinib resistance…